Social Determinants of Health Simulation

By João L. Carapinha

November 1, 2023

PhRMA’s Social Determinants of Health

Let’s look into an insightful article by Kristin Williams, published on October 27, 2023. The piece shines a light on the structural barriers patients encounter when trying to access and afford medicines. Community-level factors strongly impact healthcare access, the research shows. Nearly 40% of US counties are pharmacy deserts! These shocking numbers highlight the difficulties many encounter in accessing drugs. The article then discusses PhRMA’s Social Determinants of Health (SDOH) simulation. This novel application lets users follow a patient’s journey and demonstrate how structural and social variables impact life-saving pharmaceutical access.

Better pharmaceutical access and adherence might save the U.S. $3.8 trillion in medical bills and lost productivity. It shows how much tackling healthcare inequality matters.

It appears that insufficient insurance coverage considerably affects care access. Though true for many, insurance alone isn’t a panacea. High out-of-pocket prices, complicated approval processes, and restricted prescription formularies are common even with coverage. Thus, while insurance is important, we must also address healthcare structural challenges.

Kristin Williams’ post challenges us to address healthcare’s structural barriers and promote a more fair system. We can create a healthy future in the US and other countries.

Reference url

Recent Posts

NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced Patient Care

By HEOR Staff Writer

December 8, 2025

Digital cardiac rehabilitation is transforming how patients with cardiovascular disease access vital recovery support, and if you're wondering about the latest NICE recommendations for digital platforms in cardiac rehab, here's the key update. NICE has conditionally approved seven innovative tool...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative
EU Pilot Initiative for Repurposing Off-Patent Medicines: Core Outcomes and Regulatory Support Repurposing off-patent medicines offers a promising pathway to address unmet medical needs, p...
Innovations in Haematology Cell Therapy at ASH 2025

By HEOR Staff Writer

December 5, 2025

Advancing Haematology Cell Therapy Innovations at ASH 2025 AstraZeneca is significantly advancing haematology cell therapy with its largest-ever presence at the 67th American Society of Hematology (ASH) Annual Meeting and E...